Clinical Features of Parosmia Associated With COVID‐19 Infection
Objective To characterize the clinical features, risk factors, symptom time‐course, and quality of life implications for parosmia among coronavirus disease (COVID)‐related olfactory dysfunction patients. Methods Individuals with olfactory dysfunction associated with laboratory‐confirmed or clinicall...
Gespeichert in:
| Veröffentlicht in: | The Laryngoscope 2022-03, Vol.132 (3), p.633-639 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 639 |
|---|---|
| container_issue | 3 |
| container_start_page | 633 |
| container_title | The Laryngoscope |
| container_volume | 132 |
| creator | Lerner, David K. Garvey, Katherine L. Arrighi‐Allisan, Annie E. Filimonov, Andrey Filip, Peter Shah, Janki Tweel, Benjamin Del Signore, Anthony Schaberg, Madeleine Colley, Patrick Govindaraj, Satish Iloreta, Alfred Marc |
| description | Objective
To characterize the clinical features, risk factors, symptom time‐course, and quality of life implications for parosmia among coronavirus disease (COVID)‐related olfactory dysfunction patients.
Methods
Individuals with olfactory dysfunction associated with laboratory‐confirmed or clinically suspected COVID‐19 infection were recruited from otolaryngology and primary care practices over a period from August 2020 to March 2021. Participants completed olfactory dysfunction and quality of life surveys.
Results
A total of 148 (64.1%) of 231 respondents reported parosmia at some point. Parosmia developed within 1 week of any COVID‐19 symptom onset in 25.4% of respondents, but more than 1 month after symptom onset in 43.4% of respondents. Parosmia was associated with significantly better quantitative olfactory scores on Brief Smell Identification Test (8.7 vs. 7.5, P = .006), but demonstrated worse quality of life scores, including modified brief Questionnaire of Olfactory Dysfunction—Negative Statements and Sino‐Nasal Outcome Test‐22 scores (12.1 vs. 8.5, P |
| doi_str_mv | 10.1002/lary.29982 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9015517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2607300505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4762-988ced136a667ca374a8a9dd13e1e832b5505429c5f5ca3919c4ad3c2f4aa2ec3</originalsourceid><addsrcrecordid>eNp9kc1Kw0AUhQdRbK1ufAAJuBEhdX4ySWYj1PpXKCji72q4nUzslDRTM4nizkfwGX0SR1tFXbi6cM_H4dx7ENokuEswpnsFVM9dKkRKl1CbcEbCSAi-jNpeZGHK6W0LrTk3wZgkjONV1GJRmmDGojY66BemNAqK4FhD3VTaBTYPzqGybmog6DlnlYFaZ8GNqcdB_-x6cPj28kpEMChzrWpjy3W0kkPh9MZidtDV8dFl_zQcnp0M-r1hqKIkpqFIU6UzwmKI40QBSyJIQWR-o4lOGR1xjnlEheI597IgQkWQMUXzCIBqxTpof-47a0ZTnSld1hUUclaZqX-AtGDkb6U0Y3lvH6XAhHN_egftLAwq-9BoV8upcUoXBZTaNk7SGCcMYx_Do9t_0IltqtKf5ymaECx4Sj21O6eUf5erdP4dhmD5UY38qEZ-VuPhrZ_xv9GvLjxA5sCTKfTzP1Zy2Lu4m5u-AwoMmY4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627109582</pqid></control><display><type>article</type><title>Clinical Features of Parosmia Associated With COVID‐19 Infection</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lerner, David K. ; Garvey, Katherine L. ; Arrighi‐Allisan, Annie E. ; Filimonov, Andrey ; Filip, Peter ; Shah, Janki ; Tweel, Benjamin ; Del Signore, Anthony ; Schaberg, Madeleine ; Colley, Patrick ; Govindaraj, Satish ; Iloreta, Alfred Marc</creator><creatorcontrib>Lerner, David K. ; Garvey, Katherine L. ; Arrighi‐Allisan, Annie E. ; Filimonov, Andrey ; Filip, Peter ; Shah, Janki ; Tweel, Benjamin ; Del Signore, Anthony ; Schaberg, Madeleine ; Colley, Patrick ; Govindaraj, Satish ; Iloreta, Alfred Marc</creatorcontrib><description>Objective
To characterize the clinical features, risk factors, symptom time‐course, and quality of life implications for parosmia among coronavirus disease (COVID)‐related olfactory dysfunction patients.
Methods
Individuals with olfactory dysfunction associated with laboratory‐confirmed or clinically suspected COVID‐19 infection were recruited from otolaryngology and primary care practices over a period from August 2020 to March 2021. Participants completed olfactory dysfunction and quality of life surveys.
Results
A total of 148 (64.1%) of 231 respondents reported parosmia at some point. Parosmia developed within 1 week of any COVID‐19 symptom onset in 25.4% of respondents, but more than 1 month after symptom onset in 43.4% of respondents. Parosmia was associated with significantly better quantitative olfactory scores on Brief Smell Identification Test (8.7 vs. 7.5, P = .006), but demonstrated worse quality of life scores, including modified brief Questionnaire of Olfactory Dysfunction—Negative Statements and Sino‐Nasal Outcome Test‐22 scores (12.1 vs. 8.5, P < .001; 26.2 vs. 23.2, P = .113). Participants who developed parosmia at any point were significantly younger and less likely to have history of chronic sinusitis than those who did not develop parosmia (40.2 vs. 44.9 years, P = .007; 7.2% vs. 0.7%, P = .006).
Conclusion
COVID‐19‐associated olfactory dysfunction is frequently linked with development of parosmia, which often presents either at onset of smell loss or in a delayed fashion. Despite better quantitative olfactory scores, respondents with parosmia report decreased quality of life. A majority of respondents with persistent parosmia have sought treatment.
Level of Evidence
3 Laryngoscope, 132:633–639, 2022</description><identifier>ISSN: 0023-852X</identifier><identifier>EISSN: 1531-4995</identifier><identifier>DOI: 10.1002/lary.29982</identifier><identifier>PMID: 34870334</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Adult ; anosmia ; COVID-19 ; COVID-19 - complications ; COVID‐19 infection ; Female ; Humans ; Laryngoscopy ; Male ; Middle Aged ; Olfaction disorders ; Olfaction Disorders - virology ; Olfaction‐Chemosensation ; Olfactory dysfunction ; Pandemics ; parosmia ; Quality of Life ; Risk Factors ; SARS-CoV-2 ; Sensory perception ; Smell ; Surveys and Questionnaires</subject><ispartof>The Laryngoscope, 2022-03, Vol.132 (3), p.633-639</ispartof><rights>2021 The American Laryngological, Rhinological and Otological Society, Inc.</rights><rights>2022 The American Laryngological, Rhinological and Otological Society, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4762-988ced136a667ca374a8a9dd13e1e832b5505429c5f5ca3919c4ad3c2f4aa2ec3</citedby><cites>FETCH-LOGICAL-c4762-988ced136a667ca374a8a9dd13e1e832b5505429c5f5ca3919c4ad3c2f4aa2ec3</cites><orcidid>0000-0002-1686-6963 ; 0000-0002-6680-1252 ; 0000-0002-4285-5862 ; 0000-0002-0431-2920</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flary.29982$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flary.29982$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34870334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lerner, David K.</creatorcontrib><creatorcontrib>Garvey, Katherine L.</creatorcontrib><creatorcontrib>Arrighi‐Allisan, Annie E.</creatorcontrib><creatorcontrib>Filimonov, Andrey</creatorcontrib><creatorcontrib>Filip, Peter</creatorcontrib><creatorcontrib>Shah, Janki</creatorcontrib><creatorcontrib>Tweel, Benjamin</creatorcontrib><creatorcontrib>Del Signore, Anthony</creatorcontrib><creatorcontrib>Schaberg, Madeleine</creatorcontrib><creatorcontrib>Colley, Patrick</creatorcontrib><creatorcontrib>Govindaraj, Satish</creatorcontrib><creatorcontrib>Iloreta, Alfred Marc</creatorcontrib><title>Clinical Features of Parosmia Associated With COVID‐19 Infection</title><title>The Laryngoscope</title><addtitle>Laryngoscope</addtitle><description>Objective
To characterize the clinical features, risk factors, symptom time‐course, and quality of life implications for parosmia among coronavirus disease (COVID)‐related olfactory dysfunction patients.
Methods
Individuals with olfactory dysfunction associated with laboratory‐confirmed or clinically suspected COVID‐19 infection were recruited from otolaryngology and primary care practices over a period from August 2020 to March 2021. Participants completed olfactory dysfunction and quality of life surveys.
Results
A total of 148 (64.1%) of 231 respondents reported parosmia at some point. Parosmia developed within 1 week of any COVID‐19 symptom onset in 25.4% of respondents, but more than 1 month after symptom onset in 43.4% of respondents. Parosmia was associated with significantly better quantitative olfactory scores on Brief Smell Identification Test (8.7 vs. 7.5, P = .006), but demonstrated worse quality of life scores, including modified brief Questionnaire of Olfactory Dysfunction—Negative Statements and Sino‐Nasal Outcome Test‐22 scores (12.1 vs. 8.5, P < .001; 26.2 vs. 23.2, P = .113). Participants who developed parosmia at any point were significantly younger and less likely to have history of chronic sinusitis than those who did not develop parosmia (40.2 vs. 44.9 years, P = .007; 7.2% vs. 0.7%, P = .006).
Conclusion
COVID‐19‐associated olfactory dysfunction is frequently linked with development of parosmia, which often presents either at onset of smell loss or in a delayed fashion. Despite better quantitative olfactory scores, respondents with parosmia report decreased quality of life. A majority of respondents with persistent parosmia have sought treatment.
Level of Evidence
3 Laryngoscope, 132:633–639, 2022</description><subject>Adult</subject><subject>anosmia</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID‐19 infection</subject><subject>Female</subject><subject>Humans</subject><subject>Laryngoscopy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Olfaction disorders</subject><subject>Olfaction Disorders - virology</subject><subject>Olfaction‐Chemosensation</subject><subject>Olfactory dysfunction</subject><subject>Pandemics</subject><subject>parosmia</subject><subject>Quality of Life</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Sensory perception</subject><subject>Smell</subject><subject>Surveys and Questionnaires</subject><issn>0023-852X</issn><issn>1531-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1Kw0AUhQdRbK1ufAAJuBEhdX4ySWYj1PpXKCji72q4nUzslDRTM4nizkfwGX0SR1tFXbi6cM_H4dx7ENokuEswpnsFVM9dKkRKl1CbcEbCSAi-jNpeZGHK6W0LrTk3wZgkjONV1GJRmmDGojY66BemNAqK4FhD3VTaBTYPzqGybmog6DlnlYFaZ8GNqcdB_-x6cPj28kpEMChzrWpjy3W0kkPh9MZidtDV8dFl_zQcnp0M-r1hqKIkpqFIU6UzwmKI40QBSyJIQWR-o4lOGR1xjnlEheI597IgQkWQMUXzCIBqxTpof-47a0ZTnSld1hUUclaZqX-AtGDkb6U0Y3lvH6XAhHN_egftLAwq-9BoV8upcUoXBZTaNk7SGCcMYx_Do9t_0IltqtKf5ymaECx4Sj21O6eUf5erdP4dhmD5UY38qEZ-VuPhrZ_xv9GvLjxA5sCTKfTzP1Zy2Lu4m5u-AwoMmY4</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Lerner, David K.</creator><creator>Garvey, Katherine L.</creator><creator>Arrighi‐Allisan, Annie E.</creator><creator>Filimonov, Andrey</creator><creator>Filip, Peter</creator><creator>Shah, Janki</creator><creator>Tweel, Benjamin</creator><creator>Del Signore, Anthony</creator><creator>Schaberg, Madeleine</creator><creator>Colley, Patrick</creator><creator>Govindaraj, Satish</creator><creator>Iloreta, Alfred Marc</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1686-6963</orcidid><orcidid>https://orcid.org/0000-0002-6680-1252</orcidid><orcidid>https://orcid.org/0000-0002-4285-5862</orcidid><orcidid>https://orcid.org/0000-0002-0431-2920</orcidid></search><sort><creationdate>202203</creationdate><title>Clinical Features of Parosmia Associated With COVID‐19 Infection</title><author>Lerner, David K. ; Garvey, Katherine L. ; Arrighi‐Allisan, Annie E. ; Filimonov, Andrey ; Filip, Peter ; Shah, Janki ; Tweel, Benjamin ; Del Signore, Anthony ; Schaberg, Madeleine ; Colley, Patrick ; Govindaraj, Satish ; Iloreta, Alfred Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4762-988ced136a667ca374a8a9dd13e1e832b5505429c5f5ca3919c4ad3c2f4aa2ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>anosmia</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID‐19 infection</topic><topic>Female</topic><topic>Humans</topic><topic>Laryngoscopy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Olfaction disorders</topic><topic>Olfaction Disorders - virology</topic><topic>Olfaction‐Chemosensation</topic><topic>Olfactory dysfunction</topic><topic>Pandemics</topic><topic>parosmia</topic><topic>Quality of Life</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Sensory perception</topic><topic>Smell</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lerner, David K.</creatorcontrib><creatorcontrib>Garvey, Katherine L.</creatorcontrib><creatorcontrib>Arrighi‐Allisan, Annie E.</creatorcontrib><creatorcontrib>Filimonov, Andrey</creatorcontrib><creatorcontrib>Filip, Peter</creatorcontrib><creatorcontrib>Shah, Janki</creatorcontrib><creatorcontrib>Tweel, Benjamin</creatorcontrib><creatorcontrib>Del Signore, Anthony</creatorcontrib><creatorcontrib>Schaberg, Madeleine</creatorcontrib><creatorcontrib>Colley, Patrick</creatorcontrib><creatorcontrib>Govindaraj, Satish</creatorcontrib><creatorcontrib>Iloreta, Alfred Marc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Laryngoscope</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lerner, David K.</au><au>Garvey, Katherine L.</au><au>Arrighi‐Allisan, Annie E.</au><au>Filimonov, Andrey</au><au>Filip, Peter</au><au>Shah, Janki</au><au>Tweel, Benjamin</au><au>Del Signore, Anthony</au><au>Schaberg, Madeleine</au><au>Colley, Patrick</au><au>Govindaraj, Satish</au><au>Iloreta, Alfred Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Features of Parosmia Associated With COVID‐19 Infection</atitle><jtitle>The Laryngoscope</jtitle><addtitle>Laryngoscope</addtitle><date>2022-03</date><risdate>2022</risdate><volume>132</volume><issue>3</issue><spage>633</spage><epage>639</epage><pages>633-639</pages><issn>0023-852X</issn><eissn>1531-4995</eissn><abstract>Objective
To characterize the clinical features, risk factors, symptom time‐course, and quality of life implications for parosmia among coronavirus disease (COVID)‐related olfactory dysfunction patients.
Methods
Individuals with olfactory dysfunction associated with laboratory‐confirmed or clinically suspected COVID‐19 infection were recruited from otolaryngology and primary care practices over a period from August 2020 to March 2021. Participants completed olfactory dysfunction and quality of life surveys.
Results
A total of 148 (64.1%) of 231 respondents reported parosmia at some point. Parosmia developed within 1 week of any COVID‐19 symptom onset in 25.4% of respondents, but more than 1 month after symptom onset in 43.4% of respondents. Parosmia was associated with significantly better quantitative olfactory scores on Brief Smell Identification Test (8.7 vs. 7.5, P = .006), but demonstrated worse quality of life scores, including modified brief Questionnaire of Olfactory Dysfunction—Negative Statements and Sino‐Nasal Outcome Test‐22 scores (12.1 vs. 8.5, P < .001; 26.2 vs. 23.2, P = .113). Participants who developed parosmia at any point were significantly younger and less likely to have history of chronic sinusitis than those who did not develop parosmia (40.2 vs. 44.9 years, P = .007; 7.2% vs. 0.7%, P = .006).
Conclusion
COVID‐19‐associated olfactory dysfunction is frequently linked with development of parosmia, which often presents either at onset of smell loss or in a delayed fashion. Despite better quantitative olfactory scores, respondents with parosmia report decreased quality of life. A majority of respondents with persistent parosmia have sought treatment.
Level of Evidence
3 Laryngoscope, 132:633–639, 2022</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34870334</pmid><doi>10.1002/lary.29982</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1686-6963</orcidid><orcidid>https://orcid.org/0000-0002-6680-1252</orcidid><orcidid>https://orcid.org/0000-0002-4285-5862</orcidid><orcidid>https://orcid.org/0000-0002-0431-2920</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0023-852X |
| ispartof | The Laryngoscope, 2022-03, Vol.132 (3), p.633-639 |
| issn | 0023-852X 1531-4995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9015517 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult anosmia COVID-19 COVID-19 - complications COVID‐19 infection Female Humans Laryngoscopy Male Middle Aged Olfaction disorders Olfaction Disorders - virology Olfaction‐Chemosensation Olfactory dysfunction Pandemics parosmia Quality of Life Risk Factors SARS-CoV-2 Sensory perception Smell Surveys and Questionnaires |
| title | Clinical Features of Parosmia Associated With COVID‐19 Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T23%3A54%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Features%20of%20Parosmia%20Associated%20With%20COVID%E2%80%9019%20Infection&rft.jtitle=The%20Laryngoscope&rft.au=Lerner,%20David%20K.&rft.date=2022-03&rft.volume=132&rft.issue=3&rft.spage=633&rft.epage=639&rft.pages=633-639&rft.issn=0023-852X&rft.eissn=1531-4995&rft_id=info:doi/10.1002/lary.29982&rft_dat=%3Cproquest_pubme%3E2607300505%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627109582&rft_id=info:pmid/34870334&rfr_iscdi=true |